Angiogenesis therapies for cardiovascular disease

Current Opinion in Anaesthesiology

Volumn 16, Issue 1, 2003, Pages 3-9

  Pedrotty, Dawn M ^a   Niklason, Laura E ^a,b,c  

^a Duke University   (United States)

^b DUKE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c DUKE UNIVERSITY   (United States)

Author keywords

Angiogenesis; Cardiovascular disease; Clinical trials; Vascular growth factor

Indexed keywords

ADENOVIRUS VECTOR; ALGINIC ACID; BASIC FIBROBLAST GROWTH FACTOR; FIBROBLAST GROWTH FACTOR 4; HEPARIN DERIVATIVE; ISOPROTEIN; NITRIC OXIDE; PLASMID VECTOR; RECOMBINANT PROTEIN; RECOMBINANT VASCULOTROPIN; UNCLASSIFIED DRUG; VASCULOTROPIN; VASCULOTROPIN 165; VASCULOTROPIN A; VASCULOTROPIN C; VASCULOTROPIN RECEPTOR; VASCULOTROPIN RECEPTOR 1;

ANGIOGENESIS; BRADYCARDIA; CARDIOVASCULAR DISEASE; CELL ACTIVITY; CLINICAL TRIAL; ENDOTHELIUM CELL; GENE THERAPY; HUMAN; HYPOXIA; INTRACORONARY INFUSION; ISCHEMIC HEART DISEASE; META ANALYSIS; MICROVASCULATURE; MOLECULAR MECHANICS; PRIORITY JOURNAL; PROTEIN TRANSPORT; REVIEW; THROMBOCYTOPENIA; VIRAL GENE DELIVERY SYSTEM;

EID: 0037322755     PISSN: 09527907     EISSN: None     Source Type: Journal    
DOI: 10.1097/00001503-200302000-00002     Document Type: Review

References (44)

1. Schumacher B, Pecher P, von Specht B, et al. Induction of neoangiogenesis in ischemic myocardium by human growth factors: first clinical results of a new treatment of coronary heart disease. Circulation 1998; 97:645-650.
2. Ferrara N, Alitalo K. Clinical applications of angiogenic growth factors and their inhibitors. Nat Med 1999; 5:1359-1364.
3. Ware J, Simons M. Angiogenesis in ischemic heart disease. Nat Med 1997; 3:158-164.
4. Beck L, d'Amore P. Vascular development: cellular and molecular regulation. FASEB J 1997; 11:365-373.
5. Asahara T, Masuda H, Takahashi T, et al. VEGF contributes to postnatal neovascularization by mobilizing bone marrow-derived endothelial progenitor cells. EMBO J 1999; 18:3964-3972.
6. Asahara T, Masuda H, Takahashi T, et al. Bone marrow origin of endothelial progenitor cells responsible for postnatal vasculogenesis in physiological and pathological neovascularization. Circ Res 1999; 85:221-228.
7. Buschmann I, Schaper W. The pathophysiology of the collateral circulation (arteriogenesis). J Pathol 2000; 190:338-342.
8. Gibson C, Ryan K, Sparano A, et al. Angiographic methods to assess human coronary angiogenesis. Am Heart J 1999; 137:169-179.
9. Sasayama S, Fujita M. Recent insights into coronary collateral circulation. Circulation 1992; 85:1197-1204.
10. Tomanek R, Schatteman G. Angiogenesis: new insights and therapeutic potential. Anat Rec 2000; 261:126-135.
11. Carmeliet P. Mechanisms of angiogenesis and arteriogenesis. Nat Med 2000; 6:389-395.
12. Lamm G. The CVD programme of WHO in Europe, public health in Europe. WHO/EURO; 1981. p. 15.
13. Sellke F, Laham R, Edelman E, et al. Therapeutic angiogenesis with basic fibroblast growth factor: technique and early results. Ann Thorac Surg 1998; 65:1540-1544.
14. Hendel R, Henry T, Rocha-Singh K, et al. Effect of intracoronary recombinant human vascular endothelial growth factor on myocardial perfusion: evidence for a dose-dependent effect. Circulation 2000; 101:118-121.
15. Henry T, Rocha-Singh K, Isner J, et al. Intracoronary administration of recombinant human vascular endothelial growth factor to patients with coronary artery disease. Am Heart J 2001; 142:872-880.
16. Schumacher B, Stegmann T, Pecher P. The stimulation of neoangiogenesis in the ischemic human heart by the growth factor FGF: first clinical results. J Cardiovasc Surg 1998; 39:783-789.
17. Laham R, Sellke F, Edelman E, et al. Local perivascular delivery of basic fibroblast growth factor in patients undergoing coronary bypass surgery: results of a phase I randomized, double-blind, placebo-controlled trial. Circulation 1999; 100:1865-1871.
18. Unger E, Goncalves L, Epstein S. Effects of a single intracoronary injection of basic fibroblast growth factor in stable angina pectoris. Am J Cardiol 2000; 85:1414-1419.
19. Ferguson J. Meeting highlights: highlights of the 48th Scientific Sessions of the American College of Cardiology. Circulation 1999; 100:570-575.
20. Henry T, Azrin M, McKendall G, et al. Final results of the VIVA trial of rhVEGF for human therapeutic angiogenesis [abstract]. Circulation 1999; 100 (Suppl 1): 1-476.
21. Henry T, McKendall G, Azrin M, et al. VIVA trial: one year follow up [abstract]. Circulation 2000; 102 (Suppl II):II-309.
22. Post M, Laham R, Sellke F, et al. Therapeutic angiogenesis in cardiology using protein formulations. Cardiovasc Res 2001; 49:522-531. • Includes a discussion of the FIRST trial, the largest clinical trial using therapeutic angiogenesis.
23. Losordo D, Vale P, Symes J, et al. Gene therapy for myocardial angiogenesis: initial clinical results with direct myocardial injection of phVEGF as sole therapy for myocardial ischemia. Circulation 1998; 98:2800-2804.
24. Rosengart T, Lee L, Patel S, et al. Angiogenesis gene therapy: phase I assessment of direct intramyocardial administration of an adenovirus vector expressing VEGF121 cDNA to individuals with clinically significant severe coronary artery disease. Circulation 1999; 100:468-474.
25. Kalka C, Laudenberg B, Silver M, et al. VEGF mobilizes endothelial progenitor cells after human gene therapy for myocardial neovascularization [abstract]. Circulation 1999; 100 (Suppl):I-477.
26. Vale P, Losordo D, Milliken C. Phase I placebo controlled, double-bind, dose-escalating trial of myocardial vascular endothelial growth factor (VEGF-2) gene transfer utilizing catheter delivery in patients with chronic myocardial ischemia [abstract]. Circulation 2001; 104 (Suppl):II-253.
27. Vale P, Losordo D, Milliken C. Randomized, single-blind, placebo-controlled pilot study of catheter-based myocardial gene transfer for therapeutic angiogenesis using left ventricular electromechanical mapping in patients with chronic myocardial ischemia. Circulation 2001; 103 (17):2138-2143.
28. Kerwin T, Isner J, Leonard S, et al. Double-blind catheter-based VEGF gene transfer for myocardial ischemia: effect on myocardial perfusion assessed by SPECT imaging [abstract]. Circulation 2001; 104 (Suppl):II-456.
29. Grines C, Watkins M, Helmer G, et al. Angiogenic gene therapy (AGENT) trial in patients with stable angina pectoris. Circulation 2002; 105:1291-1297. • This article shows evidence of anti-ischemic effects using gene therapy (FGF4).
30. Losordo D, Vale P, Hendel R, et al. Phase 1/2 placebo-controlled, double-blind, dose-escalating trial of myocardial vascular endothelial growth factor 2 gene transfer by catheter delivery in patients with chronic myocardial ischemia. Circulation 2002; 105:2012-2018. • One of the first phase II clinical trials for gene therapy, demonstrating a significant reduction in anginal class, encouraging larger clinical trials.
31. Simons M, Bonaw R, Chronos N, et al. Clinical trials in coronary angiogenesis: issues, problems, consensus: an expert panel summary. Circulation 2000; 102:e73-e86.
32. Villanueva F, Abraham J, Schreiner G. Myocardial contrast echocardiography can be used to assess the microvascular response to vascular endothelial growth factor-121. Circulation 2002; 105:759-765. • The use of myocardial contrast echocardiography to evaluate the change in collateral flow due to angiogenic agents.
33. Isner J, Vale P, Symes J, Losordo DW. Assessment of risks associated with cardiovascular gene therapy in human subjects. Circ Res 2001; 89:389-400. •• A review of cardiovascular gene therapy clinical trials in regard to patient safety.
34. Freedman S, Isner J. Therapeutic angiogenesis for ischemic cardiovascular disease. J Mol Cardiol 2001; 33:379-393. •• This is a very good review of the basic science, animal studies, and early clinical trials of therapeutic angiogenesis, including potential risks and future directions.
35. Lowe H, Oesterle S, Burkhoff D. Alternatives to traditional coronary bypass surgery. Semin Thorac Cardiovasc Surg 2002; 14:110-118. •• Discussion of several novel treatments for cardiovascular disease.
36. Mueller X, Tevaearai H, Genton C, et al. Intrachannel versus interchannel application of angiogenic factors in transmyocardial laser revascularization. Swiss Surg 2001; 7:116-120. • Using a porcine model, they examined combining transmyocardial laser revascularization and angiogenic protein therapy at several locations, testing which location would be most beneficial for delivery.
37. Wang A, Nomura M, Patan S, et al. Inhibition of protein kinase C-alpha prevents endothelial cell migration and vascular tube formation in vitro and myocardial neovascularization in vivo. Circ Res 2002; 90:609-616.
38. Salvucci O, Yao L, Villalba S, et al. Regulation of endothelial cell branching morphogenesis by endogenous chemokine stromal-derived factor-1. Blood 2002; 99:2703-2711. • Examines the postnatal role of stromal-derived factor-1.
39. Nikitenko L, Smith D, Hague S, et al. Adrenomedullin and the microvasculature. Trends Pharmacol Sci 2002; 23:101-103. • Adrenomedullin was found to promote angiogenesis along with a host of other effects on the vasculature.
40. Goepfert C, Sundberg C, Sevigny J, et al. Disordered cellular migration and angiogenesis in cd39-null mice. Circulation 2001; 104:3109-3115.
41. Feoktistov I, Goldstein A, Ryzhov S, et al. Differential expression of adenosine receptors in human endothelial cells. Circ Res 2002; 90:531-538.
42. Kawamoto A, Gwon H, Iwaguro H, et al. Therapeutic potential of ex vivo expanded endothelial progenitor cells for myocardial ischemia. Circulation 2001; 103:634-637. •• Exciting results showed cultured endothelial progenitor cells injected intravenously into rats incorporated in the myocardial neovascularization, resulting in preserved function.
43. Kamihata H, Matsubara H, Nishiue T, et al. Implantation of bone marrow mononuclear cells into ischemic myocardium enhances collateral perfusion and regional function via side supply of angioblasts, angiogenic ligands, and cytokines. Circulation 2001; 104:1046-1052. •• Discussion of bone marrow implantation, leading to therapeutic angiogenesis via the secretion of angiogenic ligands, as well as incorporation into the myocardial neovascularization.
44. Eriksson U, Alitalo K. VEGF receptor 1 stimulates stem-cell recruitment and new hope for angiogenesis therapies. Nat Med 2002; 8:776-777. •• Excellent article discussing VEGF, and its receptor, in relation to inflammatory disease.